Stryker (NYSE:SYK) Given New $340.00 Price Target at JPMorgan Chase & Co.

Stryker (NYSE:SYK) had its target price cut by JPMorgan Chase & Co. from $350.00 to $340.00 in a report published on Friday morning,Benzinga reports. They currently have an overweight rating on the medical technology company’s stock.

A number of other research analysts have also recently commented on the company. Barclays dropped their price target on Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a research note on Friday. Piper Sandler lowered their target price on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a research note on Friday. Citizens Jmp dropped their target price on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a report on Friday. Finally, BTIG Research cut their price target on shares of Stryker from $316.00 to $304.00 and set a “buy” rating on the stock in a research report on Friday. Sixteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $355.44.

Stryker Trading Down 0.1%

Shares of NYSE:SYK opened at $291.56 on Friday. Stryker has a 52-week low of $267.00 and a 52-week high of $389.33. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18. The company has a market capitalization of $111.83 billion, a P/E ratio of 31.05, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78. The company has a 50-day simple moving average of $292.83 and a 200 day simple moving average of $324.51.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. During the same quarter last year, the company posted $3.19 EPS. The firm’s quarterly revenue was up 7.6% on a year-over-year basis. Sell-side analysts forecast that Stryker will post 14.85 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, September 30th. Stryker’s payout ratio is currently 37.49%.

Insider Transactions at Stryker

In other news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 over the last ninety days. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Stryker

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE bought a new position in shares of Stryker during the 2nd quarter worth $1,404,284,000. Legal & General Group Plc purchased a new stake in Stryker during the second quarter valued at about $707,212,000. Jupiter Topco LLC bought a new position in Stryker during the second quarter worth about $681,581,000. Corient Private Wealth LP bought a new stake in shares of Stryker in the second quarter valued at approximately $323,035,000. Finally, Flossbach Von Storch SE bought a new stake in shares of Stryker in the second quarter valued at approximately $464,506,000. Institutional investors own 77.09% of the company’s stock.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: JPMorgan lowered its price target from $350 to $340 but maintained an “overweight” rating, implying substantial upside from recent trading levels. Barclays also reaffirmed its “buy” rating, signaling continued confidence in Stryker’s longer-term medical-device prospects. JPMorgan Stryker rating Barclays reaffirms buy rating
• Neutral Sentiment: Analyst sentiment is mixed: Citizens JMP, Citigroup, TD Cowen, and Barclays reportedly trimmed their price targets, while Canaccord Genuity downgraded Stryker to “hold.” The changes reflect more cautious expectations rather than a broad rejection of the company’s fundamentals.
• Negative Sentiment: Stryker’s latest results fell short of forecasts. Adjusted earnings were $3.52 per share versus a $3.55 consensus estimate, while revenue of $6.52 billion missed expectations of $6.62 billion. Although revenue increased 7.6% year over year, the miss and a reset of third-quarter guidance weakened the near-term outlook. Stryker Q3 2026 earnings call transcript
• Negative Sentiment: Health-insurance headwinds were cited as an additional concern, contributing to lower fair-value estimates and multiple price-target cuts. Deutsche Bank reduced its target to $275 from $315 while retaining a “hold” rating. The stock also broke below its 50-day moving average after the disappointing report, adding technical pressure. Stryker stock down on Q3 misses Deutsche Bank adjusts Stryker price target

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.